PACB (Pacific Biosciences of California) Growth Rank: 4 (As of Aug. 07, 2026) — 43% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PACB Pacific Biosciences of California Inc PACB
55 GF Score
Price $1.17
GF Value $1.62
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Pacific Biosciences of California Growth Rank?

Pacific Biosciences of California PACB -10.38% 55 Growth Rank is 4 as of Aug. 07, 2026, which is 43% below its 10-year median of 7.00. GuruFocus rates PACB with a GF Score™ of 55/100 and a GF Value™ of $1.62 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Pacific Biosciences of California has the Growth Rank of 4.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Pacific Biosciences of California Growth Rank Related Terms

PACB vs DCTH, CLPT, SI: Growth Rank Comparison

For the Medical Devices subindustry, Pacific Biosciences of California's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pacific Biosciences of California Growth Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pacific Biosciences of California's Growth Rank distribution charts can be found below:

* The bar in red indicates where Pacific Biosciences of California's Growth Rank falls into.


PACB
55GF Score
Pacific Biosciences of California Inc PACB
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 4 mean?
Pacific Biosciences of California (PACB) has a Growth Rank of 4 as of Aug. 07, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Pacific Biosciences of California and its competitors. This is 43% below median its historical median of 7.00. Over the past decade, Pacific Biosciences of California's Growth Rank has ranged from 1.00 to 10.00.
Is Pacific Biosciences of California's Growth Rank too high?
Pacific Biosciences of California's current Growth Rank of 4 is 43% below median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Pacific Biosciences of California has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pacific Biosciences of California's Growth Rank compare to DCTH and CLPT?
Pacific Biosciences of California's Growth Rank of 4 can be compared against companies in the Medical Devices & Instruments industry. Historically, Pacific Biosciences of California's own Growth Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Devices & Instruments company?
A good Growth Rank depends on the Medical Devices & Instruments industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Pacific Biosciences of California and its competitors. Pacific Biosciences of California's current Growth Rank is 4, which is 43% below median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Biosciences of California stock overvalued right now?
Based on GuruFocus' analysis, Pacific Biosciences of California (PACB) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.62, compared to a current price of $1.17 — trading 28.1% below its estimated fair value. The current Growth Rank is 4, which is 43% below median its 10-year median of 7.00. Pacific Biosciences of California's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Pacific Biosciences of California (PACB), the current Growth Rank is 4 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacific Biosciences of California (PACB) Overvalued in 2026?

Based on GuruFocus' analysis, Pacific Biosciences of California stock appears to be undervalued. The current stock price of $1.17 is trading 28.1% below its estimated GF Value™ of $1.62. GuruFocus considers Pacific Biosciences of California to be Modestly Undervalued.

Key valuation signals for PACB:

  • Growth Rank: 4 (43% below median its 10-year median of 7.00)
  • GF Value™: $1.62 vs. price of $1.17 (28.1% below fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the PACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pacific Biosciences of California Business Description

Other Exchanges P09:Germany
Address 1305 O’Brien Drive, Menlo Park, CA, USA, 94025
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
55GF Score

Get the complete analysis for PACB

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.17
Price
$1.62
GF Value